Telor Ophthalmic Pharmaceuticals, Inc. Announces Approval of Reverse Stock Split.

WILMINGTON, Mass.--(BUSINESS WIRE)--Nov. 14, 1995--Telor Ophthalmic Pharmaceuticals, Inc. (Nasdaq: TELR TELR Talker Echo Loudness Rating ) today reported that its shareholders have approved a one-for-ten reverse stock split of its shares of Common Stock. The reverse stock split will be effective November 15, 1995. Upon the effectiveness of the reverse stock split, Telor will have approximately 785,000 shares of Common Stock outstanding. The Nasdaq symbol for Telor's Common Stock will be TELRD for the next 30 days and thereafter will be TELR.

Since its formation in 1988, Telor Ophthalmic Pharmaceuticals, Inc., a development stage company, has been engaged in research and development of products for use in ophthalmic surgery and age-related diseases of the eye. In August 1995, the Company announced that preliminary analysis of Phase III clinical trials Noun 1. phase III clinical trial - a large clinical trial of a treatment or drug that in phase I and phase II has been shown to be efficacious with tolerable side effects; after successful conclusion of these clinical trials it will receive formal approval from the of its lead product candidate, XARANO, indicated that the trials did not support continuation of the XARANO development program. Separately in August, the Company announced positive results of its Phase I/II trial of a compound to reduce surgical miosis miosis /mi·o·sis/ (mi-o´sis) contraction of the pupil.

mi·o·sis or my·o·sis
n. pl. mi·o··ses
1. , a problem associated with cataract surgery Cataract Surgery Definition

Cataract surgery is a procedure performed to remove a cloudy lens from the eye; usually an intraocular lens is implanted at the same time.
Purpose

The purpose of cataract surgery is to restore clear vision. .

CONTACT: John K. Herdklotz, Ph.D.

Acting President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board.

Telor Ophthalmic Pharmaceuticals, Inc.

508/657-8400

COPYRIGHT 1995 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.

Reader Opinion

Article Details
Printer friendly Cite/link Email Feedback
Publication:	Business Wire
Date:	Nov 14, 1995
Words:	188
Previous Article:	Telor Ophthalmic Pharmaceuticals, Inc. Announces Third Quarter Results.
Next Article:	Rockwell Automotive's new Easy Steer Plus axle virtually eliminates wheel-end maintenance.
Topics:	Ophthalmic agents Pharmaceutical industry Securities

Related Articles
Telor Ophthalmic Pharmaceuticals, Inc. Announces Results from Tekron Phase II Clinical Trial; Further Progress in Surgical Miosis and Presbyopia...
Golden Pharmaceuticals announces results of its annual meeting of shareholders; approves slate of directors; authorizes reverse stock split.
Telor Ophthalmic Pharmaceuticals, Inc. Announces Third Quarter Results.
Telor Ophthalmic Pharmaceuticals, Inc. and Occupational Health + Rehabilitation Inc, Announce Merger Agreement; Telor Ophthalmic Pharmaceuticals,...
Polydex Pharmaceuticals votes 1-for-10 reverse split of both common and preferred shares.
Procept Announces One-For-Ten Reverse Stock Split.
Access Pharmaceuticals, Inc. Announces Closing of Private Placement Funding and Implementation of Reverse Stock Split.
Idera Pharmaceuticals to Effect a Reverse Stock Split.
A.P. Pharma Stockholders Approve Reverse Stock Split.
A.P. Pharma Clarifies Effective Date of Reverse Stock Split.